Editas Medicine, Inc. (EDIT) shareholders
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.3%
120M of 154M shares
Institutional holders
215
35 new, 24 sold out
Net institutional buying
69M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $106.71K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael Kramarz Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 16,045,802 | 9.90% | 13G (passive) | May 26, 2026 |
| TCG Crossover GP III, LLC Joint filing with TCG Crossover Fund III, L.P. (9.90%), Chen Yu (9.90%) | 15,798,999 | 9.90% | 13G (passive) | May 27, 2026 |
| BlackRock, Inc. | 11,937,882 | 7.80% | 13G (passive) | Sep 30, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (5.80%) | 8,889,000 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (5.80%), Peter Kolchinsky (5.80%) and 1 more | 8,889,000 | 5.80% | 13G (passive) | May 27, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EDIT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11,111,111 | 7.23% | $36.00M | New | 0.87% |
| BlackRock, Inc. | 10,589,990 | 6.90% | $34.31M | +1,326,678 | 0.00% |
| Commodore Capital LP | 8,889,000 | 5.79% | $28.80M | New | 1.72% |
| ADAR1 Capital Management, LLC | 8,889,000 | 5.79% | $28.80M | New | 1.32% |
| Ra Capital Management, L.P. | 8,889,000 | 5.79% | $28.80M | New | 0.25% |
| Vanguard Capital Management LLC | 6,141,336 | 4.00% | $19.90M | +1,936,967 | 0.00% |
| Paradigm Biocapital Advisors LP | 5,586,625 | 3.64% | $18.10M | New | 0.34% |
| Opaleye Management Inc. | 3,861,930 | 2.51% | $12.51M | +1,934,933 | 1.13% |
| Vanguard Portfolio Management LLC | 3,598,339 | 2.34% | $11.66M | +449,769 | 0.00% |
| Woodline Partners LP | 3,555,497 | 2.32% | $11.52M | New | 0.04% |
| Vivo Capital, LLC | 3,555,250 | 2.31% | $11.52M | New | 1.05% |
| GordonMD Global Investments LP | 3,127,000 | 2.04% | $10.13M | New | 4.90% |
| Goldman Sachs Group Inc | 2,614,036 | 1.70% | $8.47M | +2,055,459 | 0.00% |
| Geode Capital Management, LLC | 2,569,072 | 1.67% | $8.33M | +257,283 | 0.00% |
| Renaissance Technologies LLC | 2,468,919 | 1.61% | $8.00M | −1,503,241 | 0.01% |
| Logos Global Management LP | 2,222,000 | 1.45% | $7.20M | New | 0.31% |
| State Street Corp | 2,191,803 | 1.43% | $7.10M | +115,681 | 0.00% |
| Marshall Wace, Llp | 2,037,287 | 1.33% | $6.60M | +1,826,979 | 0.01% |
| D. E. Shaw & Co., Inc. | 1,901,002 | 1.24% | $6.16M | −42,891 | 0.00% |
| JPMorgan Chase & Co | 1,862,494 | 1.21% | $5.96M | −84,890 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 215 | 120M | 78.3% | 35 / 76 | 41 / 24 | 74M | 6M |
| Q1 2026 | 208 | 52M | 33.8% | 38 / 58 | 51 / 24 | 17M | 7M |
| Q4 2025 | 197 | 50M | 32.6% | 29 / 46 | 60 / 21 | 12M | 5M |
| Q3 2025 | 194 | 44M | 28.6% | 24 / 47 | 57 / 23 | 8M | 6M |
| Q2 2025 | 194 | 42M | 27.1% | 26 / 47 | 53 / 26 | 6M | 9M |
| Q1 2025 | 195 | 44M | 28.7% | 24 / 45 | 60 / 34 | 8M | 14M |
| Q4 2024 | 207 | 51M | 33.2% | 39 / 60 | 58 / 58 | 11M | 15M |
| Q3 2024 | 230 | 56M | 36.4% | 37 / 67 | 64 / 41 | 16M | 10M |
| Q2 2024 | 236 | 57M | 37.2% | 49 / 65 | 72 / 37 | 6M | 20M |
| Q1 2024 | 226 | 72M | 47.2% | 38 / 73 | 62 / 35 | 16M | 4M |
| Q4 2023 | 226 | 61M | 39.8% | 39 / 54 | 73 / 34 | 9M | 9M |
| Q3 2023 | 221 | 61M | 39.7% | 25 / 76 | 62 / 40 | 10M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
140 funds held EDIT in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EDIT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,890,144 | 3.18% | $15.84M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,636,474 | 1.72% | $8.54M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,031,656 | 1.32% | $6.58M | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,100,306 | 0.72% | $3.56M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,091,084 | 0.71% | $2.81M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 844,017 | 0.55% | $2.73M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 687,467 | 0.45% | $2.23M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 509,394 | 0.33% | $1.76M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 505,306 | 0.33% | $1.75M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 476,309 | 0.31% | $1.65M | 0.01% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 415,301 | 0.27% | $1.35M | 0.04% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 336,592 | 0.22% | $1.09M | 0.07% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 291,435 | 0.19% | $1.01M | 0.01% | May 31, 2026 |
| JPMorgan Small Cap Value Fund | 278,861 | 0.18% | $903.51K | 0.07% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 278,830 | 0.18% | $903.41K | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO, Director | 286,756 | 0.19% | Nov 6, 2026 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 78,193 | 0.05% | Nov 6, 2026 |
| Daniel Scott Ory | EVP, Chief Medical Officer | – | – | Sep 9, 2026 |
| Amy Parison | SVP, Chief Financial Officer | 13,839 | 0.01% | Sep 4, 2026 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 112,720 | 0.07% | Mar 27, 2025 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 133,354 | 0.09% | Dec 5, 2024 |
| Patrick Thomas Ellinor II | Director | – | – | Aug 7, 2026 |
| Elliott M. Levy | Director | – | – | Jun 22, 2026 |
| Jessica Hopfield | Director | 67,700 | 0.04% | Jun 22, 2026 |
| Andrew Hirsch | Director | 2,000 | 0.00% | Jun 22, 2026 |
| David Scadden | Director | 0 | – | Jun 22, 2026 |
| Bernadette Connaughton | Director | 0 | – | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Nov 5, 2026 | Award | +16,533 | – | – | 78,193 |
| Gilmore Neil O'Neill CEO, Director | Nov 5, 2026 | Award | +43,567 | – | – | 286,756 |
| Amy Parison SVP, Chief Financial Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −453 | $3.04 | $1.38K | 13,839 |
| Gilmore Neil O'Neill CEO, Director | Sep 3, 2026 | Sale(10b5-1 plan) | −5,124 | $3.04 | $15.58K | 243,189 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sep 3, 2026 | Sale(10b5-1 plan) | −709 | $3.04 | $2.16K | 61,660 |
| Amy Parison SVP, Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −678 | $2.58 | $1.75K | 14,292 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 28, 2026 | Sale(10b5-1 plan) | −4,928 | $2.67 | $13.16K | 62,369 |
| Amy Parison SVP, Chief Financial Officer | Jun 3, 2026 | Sale(10b5-1 plan) | −464 | $2.70 | $1.25K | 14,970 |
| Gilmore Neil O'Neill CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −15,380 | $2.70 | $41.53K | 248,313 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jun 3, 2026 | Sale(10b5-1 plan) | −731 | $2.70 | $1.97K | 67,297 |
| Amy Parison SVP, Chief Financial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −474 | $2.02 | $957 | 15,434 |
| Gilmore Neil O'Neill CEO, Director | Mar 3, 2026 | Sale(10b5-1 plan) | −5,394 | $2.02 | $10.90K | 263,693 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Sale(10b5-1 plan) | −749 | $2.02 | $1.51K | 68,028 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Dec 3, 2025 | Sale(10b5-1 plan) | −713 | $2.15 | $1.53K | 68,777 |
| Gilmore Neil O'Neill CEO, Director | Dec 3, 2025 | Sale(10b5-1 plan) | −5,603 | $2.15 | $12.05K | 269,087 |
| Amy Parison SVP, Chief Financial Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −461 | $2.15 | $991 | 15,908 |
| Amy Parison SVP, Chief Financial Officer | Sep 3, 2025 | Sale(10b5-1 plan) | −458 | $2.60 | $1.19K | 16,369 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sep 3, 2025 | Sale(10b5-1 plan) | −710 | $2.60 | $1.85K | 69,490 |
| Gilmore Neil O'Neill CEO, Director | Sep 3, 2025 | Sale(10b5-1 plan) | −5,592 | $2.60 | $14.54K | 274,690 |
| Amy Parison SVP, Chief Financial Officer | Aug 7, 2025 | Sale(10b5-1 plan) | −679 | $2.58 | $1.75K | 16,827 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 31, 2025 | Sale(10b5-1 plan) | −5,121 | $2.49 | $12.75K | 64,398 |
| Amy Parison SVP, Chief Financial Officer | Jun 3, 2025 | Sale(10b5-1 plan) | −446 | $1.72 | $767 | 17,506 |
| Gilmore Neil O'Neill CEO, Director | Jun 3, 2025 | Sale(10b5-1 plan) | −15,192 | $1.72 | $26.13K | 280,282 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jun 3, 2025 | Sale(10b5-1 plan) | −726 | $1.72 | $1.25K | 69,519 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 4, 2025 | Sale(10b5-1 plan) | −2,891 | $1.71 | $4.94K | 70,245 |
| Gilmore Neil O'Neill CEO, Director | Mar 4, 2025 | Sale(10b5-1 plan) | −16,632 | $1.71 | $28.44K | 295,474 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 4, 2025 | Sale(10b5-1 plan) | −4,109 | $1.71 | $7.03K | 112,720 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Dec 3, 2024 | Sale(10b5-1 plan) | −541 | $2.08 | $1.13K | 133,354 |
| Gilmore Neil O'Neill CEO, Director | Dec 3, 2024 | Sale(10b5-1 plan) | −1,618 | $2.08 | $3.37K | 312,106 |
| Gilmore Neil O'Neill CEO, Director | Sep 4, 2024 | Sale(10b5-1 plan) | −1,555 | $3.42 | $5.32K | 313,724 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Sep 4, 2024 | Sale(10b5-1 plan) | −518 | $3.42 | $1.77K | 133,895 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 25, 2024 | Sale(10b5-1 plan) | −11,886 | $5.42 | $64.42K | 73,136 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Jul 19, 2024 | Sale(10b5-1 plan) | −6,619 | $5.21 | $34.48K | 134,413 |
| Gilmore Neil O'Neill CEO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −12,191 | $5.50 | $67.05K | 315,279 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Jun 4, 2024 | Sale(10b5-1 plan) | −511 | $5.50 | $2.81K | 141,032 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | May 20, 2024 | Sale(10b5-1 plan) | −22,337 | $5.61 | $125.31K | 116,829 |
| Jessica Hopfield Director | May 13, 2024 | Buy | +45,000 | $5.64 | $253.80K | 67,700 |
| Gilmore Neil O'Neill CEO, Director | Mar 5, 2024 | Sale(10b5-1 plan) | −77,824 | $9.42 | $733.10K | 327,470 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 4, 2024 | Sale(10b5-1 plan) | −20,327 | $9.42 | $191.48K | 141,543 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +19,458 | – | – | 142,413 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +19,457 | – | – | 161,870 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +50,900 | – | – | 122,955 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +130,700 | – | – | 260,869 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +72,213 | – | – | 333,082 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +72,212 | – | – | 405,294 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 2, 2024 | Award | +15,055 | – | – | 85,022 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 2, 2024 | Award | +24,800 | – | – | 69,967 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 2, 2024 | Award | +25,966 | – | – | 139,166 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 2, 2024 | Award | +35,300 | – | – | 113,200 |
| Bruce Eaton EVP, CBO AND CTO | Dec 5, 2023 | Sale(10b5-1 plan) | −103 | $10.90 | $1.12K | 74,791 |
| Bruce Eaton EVP, CBO AND CTO | Nov 14, 2023 | Sale(10b5-1 plan) | −695 | $8.21 | $5.71K | 74,894 |
| Bruce Eaton EVP, CBO AND CTO | Nov 7, 2023 | Sale(10b5-1 plan) | −139 | $8.40 | $1.17K | 75,589 |
| Bruce Eaton EVP, CBO AND CTO | Sep 6, 2023 | Sale(10b5-1 plan) | −103 | $8.82 | $908 | 75,728 |
| Bruce Eaton EVP, CBO AND CTO | Aug 11, 2023 | Sale(10b5-1 plan) | −702 | $8.59 | $6.03K | 75,831 |
| Bruce Eaton EVP, CBO AND CTO | Aug 8, 2023 | Sale(10b5-1 plan) | −141 | $8.39 | $1.18K | 76,533 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 24, 2023 | Award | +45,167 | – | – | 45,167 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Jul 19, 2023 | Sale(10b5-1 plan) | −4,317 | $8.80 | $37.99K | 72,055 |
| Gilmore Neil O'Neill CEO, Director | Jun 5, 2023 | Sale(10b5-1 plan) | −6,486 | $9.50 | $61.62K | 130,169 |
| Bruce Eaton EVP, CBO AND CTO | Jun 5, 2023 | Sale(10b5-1 plan) | −105 | $9.50 | $998 | 76,674 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | May 17, 2023 | Award | +77,900 | – | – | 77,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
25.33%
39M shares short
Days to cover
17.6
At 2M shares a day
Change since last report
+1.4%
From 38M shares
Short volume, 20 days
53.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Editas Medicine's stock actually held short. Settlement fails (shares not delivered on time) peaked at 57,754 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Linda Burkly Officer | Aug 31, 2026 | 700 | $2.30K | Sep 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 31, 2026 | 5,100 | $16.73K | Sep 3, 2026 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Jul 21, 2026 | 5,500 | $15.84K | Jul 27, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | May 29, 2026 | 15,000 | $46.20K | Jun 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Feb 27, 2026 | 6,000 | $11.34K | Mar 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Dec 1, 2025 | 7,000 | $17.50K | Dec 3, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 29, 2025 | 7,000 | $19.11K | Sep 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Aug 29, 2025 | 800 | $2.18K | Sep 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Jul 30, 2025 | 7,500 | $25.95K | Jul 31, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Jun 2, 2025 | 20,000 | $37.40K | Jun 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Feb 28, 2025 | 6,000 | $11.16K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Erick Lucera Officer | Feb 28, 2025 | 8,000 | $14.88K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Feb 28, 2025 | 35,000 | $65.10K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Baisong Mei Officer | Aug 29, 2024 | 1,000 | $3.92K | Sep 3, 2024 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 29, 2024 | 3,000 | $11.76K | Sep 3, 2024 | Restricted Stock Unit Vesting |
See a number that looks wrong?